
- Oncology NEWS International Vol 18 No 11
- Volume 18
- Issue 11
Astellas, Medivation team on prostate Rx
Astellas has partnered with Medivation to co-develop and market the oral anti-androgen, MDV3100. In September, Medivation enrolled patients in the phase III AFFIRM trial, which is evaluating MDV3100 in 1,200 men with castration-resistant prostate cancer who were previously treated with docetaxel (Doxil) chemotherapy.
Astellas has partnered with Medivation to co-develop and market the oral anti-androgen, MDV3100. In September, Medivation enrolled patients in the phase III AFFIRM trial, which is evaluating MDV3100 in 1,200 men with castration-resistant prostate cancer who were previously treated with docetaxel (Doxil) chemotherapy.
Articles in this issue
almost 16 years ago
Measure for measure: How to make practice benchmarks meaningfulalmost 16 years ago
Ultrasound targets lymph node recurrence in breast canceralmost 16 years ago
JAMA article reignites debate over screeningalmost 16 years ago
Moving at the speed of scienceNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.